The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis
Open accessAbstract
BACKGROUND: Multiparametric magnetic resonance imaging (MRI), with or without targeted biopsy, is an alternative to standard transrectal ultrasonography-guided biopsy for prostate-cancer detection in men with a raised prostate-specific antigen level who have not undergone biopsy. However, comparative evidence is limited. METHODS: In a multicenter, randomized, noninferiority trial, we assigned men with a clinical suspicion of prostate cancer who had not undergone biopsy previously to undergo MRI, with or without targeted biopsy, or standard transrectal ultrasonography-guided biopsy. Men in the MRI-targeted biopsy group underwent a targeted biopsy (without standard biopsy cores) if the MRI was suggestive of prostate cancer; men whose MRI results were not suggestive of prostate cancer were not offered biopsy. Standard biopsy was a 10-to-12-core, transrectal ultrasonography-guided biopsy. The primary outcome was the proportion of men who received a diagnosis of clinically significant cancer. Secondary outcomes included the proportion of men who received a diagnosis of clinically insignificant cancer. RESULTS: A total of 500 men underwent randomization. In the MRI-targeted biopsy group, 71 of 252 men (28%) had MRI results that were not suggestive of prostate cancer, so they did not undergo biopsy. Clinically significant cancer was detected in 95 men (38%) in the MRI-targeted biopsy group, as compared with 64 of 248 (26%) in the standard-biopsy group (adjusted difference, 12 percentage points; 95% confidence interval [CI], 4 to 20; P=0.005). MRI, with or without targeted biopsy, was noninferior to standard biopsy, and the 95% confidence interval indicated the superiority of this strategy over standard biopsy. Fewer men in the MRI-targeted biopsy group than in the standard-biopsy group received a diagnosis of clinically insignificant cancer (adjusted difference, -13 percentage points; 95% CI, -19 to -7; P<0.001). CONCLUSIONS: The use of risk assessment with MRI before biopsy and MRI-targeted biopsy was superior to standard transrectal ultrasonography-guided biopsy in men at clinical risk for prostate cancer who had not undergone biopsy previously. (Funded by the National Institute for Health Research and the European Association of Urology Research Foundation; PRECISION ClinicalTrials.gov number, NCT02380027 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., Bonsel, G., & Badia, X. (2011) · Quality of Life Research · doi:10.1007/s11136-011-9903-x · Cited by 9,795
Ahmed, H. U., El-Shater Bosaily, A., Brown, L. C., Gabe, R., Kaplan, R., Parmar, M. K., Collaco-Moraes, Y., Ward, K., Hindley, R. G., Freeman, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32401-1 · Cited by 3,284
Self-citationPI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2
Weinreb, J. C., Barentsz, J. O., Choyke, P. L., Cornud, F., Haider, M. A., Macura, K. J., Margolis, D., Schnall, M. D., Shtern, F., Tempany, C. M., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.08.052 · Cited by 2,951
Self-citation10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
Hamdy, F. C., Donovan, J. L., Lane, J. A., Mason, M., Metcalfe, C., Holding, P., Davis, M., Peters, T. J., Turner, E. L., Martin, R. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606220 · Cited by 2,640
The PRECIS-2 tool: designing trials that are fit for purpose
Loudon, K., Treweek, S., Sullivan, F., Donnan, P., Thorpe, K. E., & Zwarenstein, M. (2015) · BMJ · doi:10.1136/bmj.h2147 · Cited by 1,846
Janssen, M. F., Pickard, A. S., Golicki, D., Gudex, C., Niewada, M., Scalone, L., Swinburn, P., & Busschbach, J. (2013) · Quality of Life Research · doi:10.1007/s11136-012-0322-4 · Cited by 1,582
Siddiqui, M. M., Rais-Bahrami, S., Turkbey, B., George, A. K., Rothwax, J., Shakir, N., Okoro, C., Raskolnikov, D., Parnes, H. L., Linehan, W. M., et al. (2015) · JAMA · doi:10.1001/jama.2014.17942 · Cited by 1,505
Self-citationDickinson, L., Ahmed, H. U., Allen, C., Barentsz, J. O., Carey, B., Futterer, J. J., Heijmink, S. W., Hoskin, P. J., Kirkham, A., Padhani, A. R., et al. (2011) · European Urology · doi:10.1016/j.eururo.2010.12.009 · Cited by 737
Self-citationSchoots, I. G., Roobol, M. J., Nieboer, D., Bangma, C. H., Steyerberg, E. W., & Hunink, M. G. M. (2015) · European Urology · doi:10.1016/j.eururo.2014.11.037 · Cited by 687
Self-citationFollow-up of Prostatectomy versus Observation for Early Prostate Cancer
Wilt, T. J., Jones, K. M., Barry, M. J., Andriole, G. L., Culkin, D., Wheeler, T., Aronson, W. J., & Brawer, M. K. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615869 · Cited by 623
Cited by
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21820 · Cited by 9,533
“39 Efforts are ongoing to revitalize beneficial prostate cancer screening while mitigating the harms from overdiagnosis and overtreatment through the use of molecular markers, magnetic resonance imaging ‐ targeted biopsy, 40,41 and active surveillance of low ‐ risk disease.”
BackgroundMottet, N., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.042 · Cited by 2,802
Artificial intelligence in cancer imaging: Clinical challenges and applications
Bi, W. L., Hosny, A., Schabath, M. B., Giger, M. L., Birkbak, N. J., Mehrtash, A., Allison, T., Arnaout, O., Abbosh, C., Dunn, I. F., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21552 · Cited by 1,846
Cornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Brunckhorst, O., Darraugh, J., Eberli, D., De Meerleer, G., De Santis, M., Farolfi, A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.03.027 · Cited by 1,246
Rouvière, O., Puech, P., Renard-Penna, R., Claudon, M., Roy, C., Mège-Lechevallier, F., Decaussin-Petrucci, M., Dubreuil-Chambardel, M., Magaud, L., Remontet, L., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30569-2 · Cited by 1,095
Self-citationRebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,090
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tombal, B., & Gillessen, S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.011 · Cited by 977
Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches
Sekhoacha, M., Riet, K., Motloung, P., Gumenku, L., Adegoke, A., & Mashele, S. (2022) · Molecules · doi:10.3390/molecules27175730 · Cited by 904
van der Leest, M., Cornel, E., Israël, B., Hendriks, R., Padhani, A. R., Hoogenboom, M., Zamecnik, P., Bakker, D., Setiasti, A. Y., Veltman, J., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.11.023 · Cited by 777
The Lancet Commission on prostate cancer: planning for the surge in cases
James, N. D., Tannock, I., N'Dow, J., Feng, F., Gillessen, S., Ali, S. A., Trujillo, B., Al-Lazikani, B., Attard, G., Bray, F., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00651-2 · Cited by 738
Self-citationvan Leenders, G. J. L. H., van der Kwast, T. H., Grignon, D. J., Evans, A. J., Kristiansen, G., Kweldam, C. F., Litjens, G., McKenney, J. K., Melamed, J., Mottet, N., et al. (2020) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001497 · Cited by 713
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer
Hugosson, J., Roobol, M. J., Månsson, M., Tammela, T. L. J., Zappa, M., Nelen, V., Kwiatkowski, M., Lujan, M., Carlsson, S. V., Talala, K. M., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.02.009 · Cited by 698
Self-citationIlic, D., Djulbegovic, M., Jung, J. H., Hwang, E. C., Zhou, Q., Cleves, A., Agoritsas, T., & Dahm, P. (2018) · BMJ · doi:10.1136/bmj.k3519 · Cited by 641
Drost, F.-J. H., Osses, D. F., Nieboer, D., Steyerberg, E. W., Bangma, C. H., Roobol, M. J., & Schoots, I. G. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012663.pub2 · Cited by 640
Self-citationSandhu, S., Moore, C. M., Chiong, E., Beltran, H., Bristow, R. G., & Williams, S. G. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00950-8 · Cited by 583
Self-citationCancer statistics for African American/Black People 2022
Giaquinto, A. N., Miller, K. D., Tossas, K. Y., Winn, R. A., Jemal, A., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21718 · Cited by 574
The future of early cancer detection
Fitzgerald, R. C., Antoniou, A. C., Fruk, L., & Rosenfeld, N. (2022) · Nature Medicine · doi:10.1038/s41591-022-01746-x · Cited by 457
Emmett, L., Buteau, J., Papa, N., Moon, D., Thompson, J., Roberts, M. J., Rasiah, K., Pattison, D. A., Yaxley, J., Thomas, P., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.08.002 · Cited by 430
Westphalen, A. C., McCulloch, C. E., Anaokar, J. M., Arora, S., Barashi, N. S., Barentsz, J. O., Bathala, T. K., Bittencourt, L. K., Booker, M. T., Braxton, V. G., et al. (2020) · Radiology · doi:10.1148/radiol.2020190646 · Cited by 422
Self-citationMRI-Targeted or Standard Biopsy in Prostate Cancer Screening
Eklund, M., Jäderling, F., Discacciati, A., Bergman, M., Annerstedt, M., Aly, M., Glaessgen, A., Carlsson, S., Grönberg, H., & Nordström, T. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100852 · Cited by 400
Multiparametric MRI for prostate cancer diagnosis: current status and future directions
Stabile, A., Giganti, F., Rosenkrantz, A. B., Taneja, S. S., Villeirs, G., Gill, I. S., Allen, C., Emberton, M., Moore, C. M., & Kasivisvanathan, V. (2020) · Nature Reviews Urology · doi:10.1038/s41585-019-0212-4 · Cited by 398
Self-citationProstate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only
Hugosson, J., Månsson, M., Wallström, J., Axcrona, U., Carlsson, S. V., Egevad, L., Geterud, K., Khatami, A., Kohestani, K., Pihl, C.-G., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2209454 · Cited by 381
Drost, F.-J. H., Osses, D., Nieboer, D., Bangma, C. H., Steyerberg, E. W., Roobol, M. J., & Schoots, I. G. (2020) · European Urology · doi:10.1016/j.eururo.2019.06.023 · Cited by 370
Self-citationClassification of Cancer at Prostate MRI: Deep Learning versus Clinical PI-RADS Assessment
Schelb, P., Kohl, S., Radtke, J. P., Wiesenfarth, M., Kickingereder, P., Bickelhaupt, S., Kuder, T. A., Stenzinger, A., Hohenfellner, M., Schlemmer, H.-P., et al. (2019) · Radiology · doi:10.1148/radiol.2019190938 · Cited by 326
de Rooij, M., Israël, B., Tummers, M., Ahmed, H. U., Barrett, T., Giganti, F., Hamm, B., Løgager, V., Padhani, A., Panebianco, V., et al. (2020) · European Radiology · doi:10.1007/s00330-020-06929-z · Cited by 324
Self-citationGandaglia, G., Ploussard, G., Valerio, M., Mattei, A., Fiori, C., Fossati, N., Stabile, A., Beauval, J.-B., Malavaud, B., Roumiguié, M., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.10.012 · Cited by 322
Self-citationGiganti, F., Allen, C., Emberton, M., Moore, C. M., & Kasivisvanathan, V. (2020) · European Urology Oncology · doi:10.1016/j.euo.2020.06.007 · Cited by 315
Self-citationGenomics of lethal prostate cancer at diagnosis and castration resistance
Mateo, J., Seed, G., Bertan, C., Rescigno, P., Dolling, D., Figueiredo, I., Miranda, S., Nava Rodrigues, D., Gurel, B., Clarke, M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci132031 · Cited by 313
Wegelin, O., Exterkate, L., van der Leest, M., Kummer, J. A., Vreuls, W., de Bruin, P. C., Bosch, J. L. H. R., Barentsz, J. O., Somford, D. M., & van Melick, H. H. E. (2019) · European Urology · doi:10.1016/j.eururo.2018.11.040 · Cited by 291
Padhani, A. R., Weinreb, J., Rosenkrantz, A. B., Villeirs, G., Turkbey, B., & Barentsz, J. (2019) · European Urology · doi:10.1016/j.eururo.2018.05.035 · Cited by 288
Self-citationXiang, J., Yan, H., Li, J., Wang, X., Chen, H., & Zheng, X. (2019) · World Journal of Surgical Oncology · doi:10.1186/s12957-019-1573-0 · Cited by 272
Winkel, D. J., Tong, A., Lou, B., Kamen, A., Comaniciu, D., Disselhorst, J. A., Rodríguez-Ruiz, A., Huisman, H., Szolar, D., Shabunin, I., et al. (2021) · Investigative Radiology · doi:10.1097/rli.0000000000000780 · Cited by 118
Sunoqrot, M. R. S., Saha, A., Hosseinzadeh, M., Elschot, M., & Huisman, H. (2022) · European Radiology Experimental · doi:10.1186/s41747-022-00288-8 · Cited by 76
Machine learning in prostate MRI for prostate cancer: current status and future opportunities
Li, H., Lee, C. H., Chia, D., Lin, Z., Huang, W., & Tan, C. H. (2022) · Diagnostics · doi:10.3390/diagnostics12020289 · Cited by 74
“MRI-guided targeted biopsy pathways have been shown to improve the detection of clinically significant prostate cancer with a reduction in the number of biopsy cores, compared to conventional systematic biopsy [3,4].”
Background
Metadata
- Authors
- Kasivisvanathan, V., Rannikko, A. S., Borghi, M., Panebianco, V., Mynderse, L. A., Vaarala, M. H., Briganti, A., Budäus, L., Hellawell, G., Hindley, R. G., Roobol, M. J., Eggener, S., Ghei, M., Villers, A., Bladou, F., Villeirs, G. M., Virdi, J., Boxler, S., Robert, G., Singh, P. B., Venderink, W., Hadaschik, B. A., Ruffion, A., Hu, J. C., Margolis, D., Crouzet, S., Klotz, L., Taneja, S. S., Pinto, P., Gill, I., Allen, C., Giganti, F., Freeman, A., Morris, S., Punwani, S., Williams, N. R., Brew-Graves, C., Deeks, J., Takwoingi, Y., Emberton, M., & Moore, C. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-10
- Volume
- 378
- Issue
- 19
- Pages
- 1767-1777
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2793905111
- Cited by
- 3,091
- References
- 18
- FWCI
- 227.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.